CTI Proposal Process

CTI Proposal Process

JHU–Pfizer CTI HOME | CTI Proposal Process
JHU and Pfizer CTI Joint Steering Committee | Frequently Asked Questions

The CTI program has two calls for proposals each year. The next scheduled call will close on April 23, 2018.

All Johns Hopkins researchers and clinicians whose work meets these criteria are invited to apply to collaborate with CTI. The first step is submitting a two- to three-page, non-confidential pre-proposal, providing an overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should explain how the therapeutic hypothesis could be tested in the clinic. Pre-proposals should be submitted to CTI by JHTV.

The Johns Hopkins University and Pfizer CTI Joint Steering Committee will review all submitted proposals. For selected projects, a team of scientists from CTI and Johns Hopkins investigators will work together to submit a more detailed proposal, including a project plan to advance the research. Pre-proposal responses for spring 2018 submissions will be sent in early 2018.


Therapeutic Areas of Interest

  • Oncology: immuno-oncology; epigenetics targets; novel, tumor-specific, cell-surface antigens; and targets identified by unique insights in tumor biology
  • Inflammation and immune disorders: Crohn’s disease and colitis, gastrointestinal disorders, and rheumatoid arthritis
  • Cardiovascular and metabolic diseases: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and heart failure
  • Rare monogenic genetic diseases: hematologic, neuromuscular, pulmonary and inherited metabolic/endocrine diseases


Project Scope

  • As a general rule, CTI does not accept research proposals in the following areas: radiotherapy and vaccines.
  • Pre-proposals for collaboration will be evaluated initially on the basis of fit with Pfizer internal program portfolios, other CTI collaborations, and business and technical feasibility specific to each project.


Success Factors: What CTI Looks For

  • Strong project rationale
    • Demonstrated association between target biology, pathway, and disease mechanism
    • Target validation as demonstrated by genetic or pharmacologic evidence
  • Ability to address unmet medical needs
  • Validated therapeutic drug target
    • Tractable target relative to proposed drug modalities (antibodies, proteins and peptides)
    • Novel target, novel therapeutic strategy or new insight into target patient population
    • Defined target
    • Understanding of desired pharmacology
    • Demonstrated cause-effect relationship to disease mechanism
  • Project feasibility
    • Clear path to candidate development (biochemical/cell-free/cellular assays, disease models, preclinical testing, etc.)
    • Clear path for translation into clinical trials (approach for proof of mechanism in humans, accessible patient population, time frame, safety issues, etc.)
  • Clinical differentiation
    • Therapeutic strategies, including personalized medicine, patient stratification, molecular signatures, genetic associations, and biomarkers
  • Modalities
    • Small molecules
    • Large molecules (antibodies, proteins, peptides, antibody drug conjugates, and fusion proteins)








  • Submission to Johns Hopkins Technology Ventures (JHTV, Sean Evans) begins: Monday, March 19, 2018
  • Deadline for submission to Johns Hopkins Technology Ventures (JHTV, Sean Evans): Monday, April 23, 2018
  • Deadline for JHTV to submit to CTI: Monday, April 30, 2018



  • CTI’s Nader Halim will hold regular office hours to NON-CONFIEDENTIALLY discuss potential pre-proposal ideas in preparation for submission. Scheduling details being worked out
  • Dates: Thursday, April 5 & Friday, April 13, 2018
  • Time: 11 A.M. – 4 P.M.
  • Location: JHTV